XVIVO Delays Q1 2026 Report to Spotlight Key U.S. Heart Study

Xvivo Perfusion AB ( (SE:XVIVO) ) has issued an update.

XVIVO Perfusion AB has rescheduled the publication of its interim report for the January–March 2026 period, moving the release to Friday, April 24, 2026, from the previously planned date of Wednesday, April 22. The company said the adjustment is necessary because the initial reporting date overlaps with the presentation of its U.S. heart preservation study, PRESERVE, at the ISHLT conference in Toronto, signaling the strategic importance of the clinical data showcase for its transplant-focused portfolio.

By prioritizing the timing of the PRESERVE study presentation, XVIVO underscores the central role that heart preservation technology and clinical evidence play in its growth trajectory and visibility in the transplant medicine community. Investors and other stakeholders will receive the quarterly financial update two days later than planned, but the move suggests the company is concentrating efforts on maximizing the impact of its scientific results among key opinion leaders and potential partners in its core market.

The most recent analyst rating on (SE:XVIVO) stock is a Hold with a SEK210.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.

More about Xvivo Perfusion AB

XVIVO Perfusion AB is a Sweden-based medical technology company focused on extending the life of all major organs to enable more successful transplant procedures worldwide. Founded in 1998 and headquartered in Gothenburg, the Nasdaq Stockholm-listed group develops solutions that help clinicians and researchers advance the boundaries of transplantation medicine, supported by offices and research sites across two continents.

Average Trading Volume: 184,482

Technical Sentiment Signal: Sell

Current Market Cap: SEK6.33B

Find detailed analytics on XVIVO stock on TipRanks’ Stock Analysis page.